Try our beta test site
Trial record 1 of 2 for:    ipf vismodegib
Previous Study | Return to List | Next Study

A Safety and Tolerability Study of Oral Vismodegib in Combination With Pirfenidone in Participants With Idiopathic Pulmonary Fibrosis

This study is currently recruiting participants. (see Contacts and Locations)
Verified July 2016 by Hoffmann-La Roche
Information provided by (Responsible Party):
Hoffmann-La Roche Identifier:
First received: January 5, 2016
Last updated: July 1, 2016
Last verified: July 2016
This is a single arm, multicenter, open-label, Phase 1b study to evaluate the safety and tolerability of vismodegib in combination with pirfenidone in participants with idiopathic pulmonary fibrosis (IPF) currently being treated with pirfenidone.

Condition Intervention Phase
Idiopathic Pulmonary Fibrosis
Drug: Pirfenidone
Drug: Vismodegib
Phase 1

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Single Arm, Multicenter, Open-label, Phase 1b Study to Assess the Safety and Tolerability of Oral Vismodegib in Combination With Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis

Resource links provided by NLM:

Further study details as provided by Hoffmann-La Roche:

Primary Outcome Measures:
  • Percentage of participants with serious and non-serious adverse events [ Time Frame: Up to 28 weeks ]
  • Percentage of participants with discontinuation of any study medication [ Time Frame: Up to Week 24 ]
  • Percentage of participants with dose modifications due to laboratory abnormalities and clinical adverse events [ Time Frame: Up to Week 24 ]
  • Percentage of Participants with Abnormal Vital Signs and Abnormal Clinical Laboratory Parameters, as assessed by Investigator [ Time Frame: Up to 28 weeks ]

Estimated Enrollment: 20
Study Start Date: January 2016
Estimated Study Completion Date: December 2016
Estimated Primary Completion Date: December 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Vismodegib+pirfenidone
Participants will receive 150 mg vismodegib once daily and up to 2403 mg pirfenidone daily via oral administration for 24 weeks.
Drug: Pirfenidone
Participants will receive up to 2403 mg pirfenidone daily via oral administration for 24 weeks.
Other Name: RO0220912
Drug: Vismodegib
Participants will receive 150 mg vismodegib once daily via oral administration for 24 weeks.
Other Name: RO5450815


Ages Eligible for Study:   40 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Have a diagnosis of IPF 5 years from time of screening, confirmed at baseline
  • Tolerated dose of pirfenidone 1602-2403 mg once daily (QD) for a minimum of 24 weeks required prior to and during screening
  • Greater than or equal to (>=) 50 percent (%) and <=100% of predicted forced vital capacity (FVC) at screening
  • Stable baseline lung function as evidenced by a difference of less than (<) 10% in absolute FVC measurements (in liters) between screening and Day 1/Visit 2 prior to enrollment
  • >=30% and <=90% of predicted diffusion capacity of the lung for carbon monoxide at screening
  • Agree to use protocol defined methods of contraception
  • Male participants must agree not to donate semen during the study and for at least 2 months (or as per local requirements) after the last dose of vismodegib
  • Agree not to donate blood or blood products during the study and for at least 9 months (or as per local requirements) after the last dose of study treatment

Exclusion Criteria:

  • Prior treatment with vismodegib or any Hh-pathway inhibitor
  • Evidence of other known causes of interstitial lung disease
  • Hospitalization due to an exacerbation of IPF within 4 weeks prior to or during screening
  • Lung transplant expected within 6 months of screening
  • Evidence of clinically significant lung disease other than IPF
  • Post-bronchodilator forced expiratory volume in 1 second/FVC ratio <0.7 at screening
  • Any clinically significant medical disease (other than IPF) that is associated with an expected survival of <6 months, likely to require a change in therapy during the study
  • Class IV New York Heart Association chronic heart failure or historical evidence of left ventricular ejection fraction <35%
  • Known current malignancy or current evaluation for a potential malignancy
  • Known immunodeficiency, including, but not limited to, human immunodeficiency virus infection
  • Evidence of acute or chronic hepatitis or known liver cirrhosis
  • Creatinine clearance <30 milliliter per minute, calculated using the Cockcroft-Gault formula
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT02648048

Contact: Reference Study ID Number: GB29764 888-662-6728 (U.S. and Canada)

United States, California
La Jolla, California, United States, 92037
United States, Florida
Active, not recruiting
Orlando, Florida, United States, 32803
United States, Illinois
Active, not recruiting
Elk Grove, Illinois, United States, 60007
United States, Indiana
Muncie, Indiana, United States, 47303
United States, Kentucky
Active, not recruiting
Louisville, Kentucky, United States, 40202-1798
United States, Louisiana
Active, not recruiting
New Orleans, Louisiana, United States, 70112
United States, Massachusetts
Active, not recruiting
Boston, Massachusetts, United States, 02135
United States, Nebraska
Omaha, Nebraska, United States, 68131
United States, Nevada
Reno, Nevada, United States, 89503
United States, New Jersey
Summit, New Jersey, United States, 07901
United States, North Carolina
Active, not recruiting
Greensboro, North Carolina, United States, 27403
Active, not recruiting
Wilmington, North Carolina, United States, 28401
United States, Washington
Everett, Washington, United States, 98208
Active, not recruiting
Seattle, Washington, United States, 98122
Active, not recruiting
Hannover, Germany, 30625
Sponsors and Collaborators
Hoffmann-La Roche
Study Director: Clinical Trials Hoffmann-La Roche
  More Information

Responsible Party: Hoffmann-La Roche Identifier: NCT02648048     History of Changes
Other Study ID Numbers: GB29764  2015-003481-81 
Study First Received: January 5, 2016
Last Updated: July 1, 2016

Keywords provided by Hoffmann-La Roche:
Idiopathic Pulmonary Fibrosis

Additional relevant MeSH terms:
Idiopathic Pulmonary Fibrosis
Pulmonary Fibrosis
Idiopathic Interstitial Pneumonias
Pathologic Processes
Lung Diseases, Interstitial
Lung Diseases
Respiratory Tract Diseases
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Anti-Inflammatory Agents
Antirheumatic Agents
Antineoplastic Agents processed this record on February 20, 2017